Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Histamine-2 Receptor Antagonist Versus Proton-Pump Inhibitor for the Prevention of Recurrent Upper Gastrointestinal Bleeding (UGI) in High-risk Users of Low-dose Aspirin (ASA)

Next Previous
Trial Profile

Histamine-2 Receptor Antagonist Versus Proton-Pump Inhibitor for the Prevention of Recurrent Upper Gastrointestinal Bleeding (UGI) in High-risk Users of Low-dose Aspirin (ASA)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 May 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rabeprazole (Primary) ; Famotidine
  • Indications Peptic ulcer
  • Focus Therapeutic Use
  • Acronyms ASP(PPI-H2RA)

Most Recent Events

  • 20 Apr 2017 Status changed from active, no longer recruiting to completed.
  • 15 Sep 2016 Results published in the Gastroenterology.
  • 11 Sep 2016 Primary endpoint (Recurrent non-variceal upper GI bleeding) has not been met, according to results published in the Gastroenterology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top